Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism
The DOI matches its Crossref record, with a small difference in title or year; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Warfarin is very effective in preventing recurrent venous thromboembolism but is also associated with a substantial risk of bleeding. After three months of conventional warfarin therapy, a lower dose of anticoagulant medication may result in less bleeding and still prevent recurrent venous thromboembolism. METHODS: We conducted a randomized, double-blind study, in which 738 patients who had completed three or more months of warfarin therapy for unprovoked venous thromboembolism were randomly assigned to continue warfarin therapy with a target international normalized ratio (INR) of 2.0 to 3.0 (conventional intensity) or a target INR of 1.5 to 1.9 (low intensity). Patients were followed for an average of 2.4 years. RESULTS: Of 369 patients assigned to low-intensity therapy, 16 had recurrent venous thromboembolism (1.9 per 100 person-years), as compared with 6 of 369 assigned to conventional-intensity therapy (0.7 per 100 person-years; hazard ratio, 2.8; 95 percent confidence interval, 1.1 to 7.0). A major bleeding episode occurred in nine patients assigned to low-intensity therapy (1.1 events per 100 person-years) and eight patients assigned to conventional-intensity therapy (0.9 event per 100 person-years; hazard ratio, 1.2; 95 percent confidence interval, 0.4 to 3.0). There was no significant difference in the frequency of overall bleeding between the two groups (hazard ratio, 1.3; 95 percent confidence interval, 0.8 to 2.1). CONCLUSIONS: Conventional-intensity warfarin therapy is more effective than low-intensity warfarin therapy for the long-term prevention of recurrent venous thromboembolism. The low-intensity warfarin regimen does not reduce the risk of clinically important bleeding.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We identified 1 RCT 317 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [316]
In the citing paper
“However, it should be noted that patients considered to have a ' high risk of bleeding ' were excluded from the randomized trial described in the analysis above. 316”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [316]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181 · cited 1×
“[7] Hazard ratios associated with low-intensity therapy as compared with conventional-intensity therapy (with 95 percent confidence intervals) and log-rank tests were used to compare the treatment groups.”
MethodNonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Mutation in blood coagulation factor V associated with resistance to activated protein C
Bertina, R. M., Koeleman, B. P. C., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994) · Nature · doi:10.1038/369064a0 · Cited by 3,783
Poort, Sr., Rosendaal, F., Reitsma, P., & Bertina, R. (1996) · Blood · doi:10.1182/blood.v88.10.3698.bloodjournal88103698 · Cited by 3,079 · cited 1×
“Assays for factor V Leiden [4] and the G20210A mutation in the prothrombin gene [5] were performed in a central laboratory by technologists who were unaware of the patient's treatment-group assignment and clinical course.”
MethodOral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H., Ansell, J., & Deykin, D. (2001) · Chest · doi:10.1378/chest.119.1_suppl.8s · Cited by 1,804 · cited 1×
“0 per 100 patient-years among those assigned to low-intensity therapy, [6] an average of 2.”
BackgroundSelf-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072 · cited 5×
“As in other studies, [2,10] factor V Leiden and prothrombin-gene mutations were not associated with a higher risk of recurrent thromboembolism, although all patients in our study were treated with anticoagulant therapy.”
BackgroundResultInfluentialSelf-citationNatural History of Venous Thromboembolism
Kearon, C. (2003) · Circulation · doi:10.1161/01.cir.0000078464.82671.78 · Cited by 1,048
Self-citationLong-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808 · cited 2×
“Collectively, the results of our study and the three other trials that have evaluated extended treatment of patients who have had unprovoked venous thromboembolism [2,3,9] suggest that low-intensity anticoagulant therapy reduces the risk of recurrent thrombosis by about 75 percent, whereas conventional-intensity thera…”
BackgroundResultBeyth, R. J., Quinn, L. M., & Landefeld, C. S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00198-3 · Cited by 773
Research works printed but not linked: 3
- Kearon C, 2003, Circulation, 107, I
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Mantel N, 1966, Cancer Chemother Rep, 50, 163
Cited by
Items 101–200 of 748
Annals Journal Club: It's Time to Get RADICAL
Stange, K. C. (2006) · The Annals of Family Medicine · doi:10.1370/afm.588 · Cited by 112
Ageno, W., Antonucci, E., Cosmi, B., Kovacs, M. J., Gal, G. L., Ockelford, P., Poli, D., Prandoni, P., Rodger, M., Saccullo, G., et al. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-04-0336 · Cited by 111
Self-citationSelf-monitoring and self-management of oral anticoagulation
Garcia-Alamino, J. M., Ward, A. M., Alonso-Coello, P., Perera, R., Bankhead, C., Fitzmaurice, D., & Heneghan, C. J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003839.pub2 · Cited by 109
Splanchnic vein thrombosis in severe acute pancreatitis: a 2-year, single-institution experience
Gonzelez, H. J., Sahay, S., Samadi, B., Davidson, B. R., & Rahman, S. H. (2011) · HPB · doi:10.1111/j.1477-2574.2011.00392.x · Cited by 108
Pernod, G., Labarère, J., Yver, J., Satger, B., Allenet, B., Berremili, T., Fontaine, M., Franco, G., & Bosson, J. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0690-1 · Cited by 103
Levi, M. M., Hovingh, G. K., Cannegieter, S. C., Vermeulen, M., Buller, H. R., & Rosendaal, F. R. (2008) · Blood · doi:10.1182/blood-2007-11-123711 · Cited by 110
“Not suitable for anticoagulation 30 (14) 25 (13) Cardiac comorbidity 34 ( 16 ) 23 (12) Comedication* 70 (33) 28 (14)”
Delivery of Optimized Anticoagulant Therapy: Consensus Statement from the Anticoagulation Forum
Garcia, D. A., Witt, D. M., Hylek, E. M., Wittkowsky, A. K., Nutescu, E. A., Jacobson, A. K., Moll, S., Merli, G. J., Crowther, M. A., Earl, L. E., et al. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1l098 · Cited by 102
Self-citationPrognostic Value of ECG Among Patients with Acute Pulmonary Embolism and Normal Blood Pressure
Vanni, S., Polidori, G., Vergara, R., Pepe, G., Nazerian, P., Moroni, F., Garbelli, E., Daviddi, F., & Grifoni, S. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.08.031 · Cited by 106
Acute Pulmonary Embolism: Part II: Treatment and Prophylaxis
Piazza, G., & Goldhaber, S. Z. (2006) · Circulation · doi:10.1161/circulationaha.106.620880 · Cited by 114
Invasive Approaches to Treatment of Venous Thromboembolism
Augustinos, P., & Ouriel, K. (2004) · Circulation · doi:10.1161/01.cir.0000140900.64198.f4 · Cited by 104
The diagnosis and treatment of venous thromboembolism in Asian patients
Wang, K.-L., Yap, E. S., Goto, S., Zhang, S., Siu, C., & Chiang, C. (2018) · Thrombosis Journal · doi:10.1186/s12959-017-0155-z · Cited by 104
Suzuki, S. S., Yamashita, T., Kato, T., Fujino, T., Sagara, K., Sawada, H., Aizawa, T., & Fu, L.-T. (2007) · Circulation Journal · doi:10.1253/circj.71.761 · Cited by 101
Humphries, S. E., Ridker, P. M., & Talmud, P. J. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000116216.56511.39 · Cited by 102
Kooiman, J., van Hagen, N., del Sol, A. I., Planken, E. V., Lip, G. Y. H., van der Meer, F. J. M., Cannegieter, S. C., Klok, F. A., & Huisman, M. V. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122520 · Cited by 102
New oral antithrombotics: a need for laboratory monitoring. For
Mismetti, P., & Laporte, S. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03764.x · Cited by 91
Vasanthamohan, L., Boonyawat, K., Chai‐Adisaksopha, C., & Crowther, M. A. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14156 · Cited by 93
Self-citationGianesini, S., Obi, A. T., Onida, S., Baccellieri, D., Bissacco, D., Борсук, Д. А., Campisi, C., Campisi, C. C., Cavezzi, A., Chi, Y., et al. (2019) · Phlebology The Journal of Venous Disease · doi:10.1177/0268355519870690 · Cited by 99
The population pharmacokinetics of R‐ and S‐warfarin: effect of genetic and clinical factors
Lane, S., Alzubiedi, S., Hatch, E., Matthews, I., Jorgensen, A., Deloukas, P., Daly, A. K., Park, B. K., Aarons, L. J., Ogungbenro, K., et al. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04051.x · Cited by 89
Can haematological tests predict cardiovascular risk? The 2005 Kettle Lecture*
Lowe, G. D. O. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06021.x · Cited by 96
“Several recent randomised trials of extended anticoagulation have shown its efficacy in prevention of recurrence, compared with standard duration anticoagulation (Schulman et al, 1995, 2003; Kearon et al, 1999, 2003; Ridker et al, 2003; Goldhaber, 2004).”
BackgroundWarfarin anticoagulation reversal: management of the asymptomatic and bleeding patient
Makris, M., van Veen, J. J., & Maclean, R. (2009) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-009-0412-5 · Cited by 91
“9/100 pt/years in the standard intensity group) [7].”
BackgroundCushman, M., Glynn, R. J., Goldhaber, S. Z., Moll, S., Bauer, K. A., Deitcher, S. R., SHRIVASTAVA, S., & Ridker, P. M. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02140.x · Cited by 85
Timp, J. F., Lijfering, W. M., Flinterman, L. E., Vlieg, A. V. H., le Cessie, S., Rosendaal, F. R., & Cannegieter, S. C. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13113 · Cited by 85
Erkens, P. M. G., Cate, H. T., Buller, H. R., & Prins, M. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042269 · Cited by 84
“Twenty (50%) studies [15,16,17,18,19,25, 27,28,29,30,31,33,35,37,41,45,47,48,49,50] reported that they calculated the TTR by using linear interpolation [52].”
BackgroundTreatment of venous thromboembolism
Buller, H. R., Söhne, M., & Middeldorp, S. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01414.x · Cited by 98
SHRIVASTAVA, S., Ridker, P. M., Glynn, R. J., Goldhaber, S. Z., Moll, S., Bounameaux, H., Bauer, K. A., Kessler, C. M., & Cushman, M. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01935.x · Cited by 84
Scherz, N., Méan, M., Limacher, A., Righini, M., Jaeger, K. A., Beer, J. H., Frauchiger, B., Osterwalder, J. J., Kucher, N., Matter, C. M., et al. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12111 · Cited by 87
How I treat the antiphospholipid syndrome
Giannakopoulos, B., & Krilis, S. A. (2009) · Blood · doi:10.1182/blood-2009-05-220756 · Cited by 86
Self-Managed Long-Term Low-Molecular-Weight Heparin Therapy: The Balance of Benefits and Harms
Hull, R. D., Pineo, G. F., Brant, R., Mah, A. F., Burke, N., Dear, R., Wong, T., Cook, R., Solymoss, S., Poon, M., et al. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.03.030 · Cited by 88
Self-citationClinical Characteristics and Long-term Follow-up of Patients With Renal Vein Thrombosis
Wysokiński, W. E., Gosk−Bierska, I., Greene, E. L., Grill, D. E., Wiste, H. J., & McBane, R. D. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.10.030 · Cited by 82
Clinical outcome of experimental human malaria induced by Plasmodium falciparum-infected mosquitoes.
Verhage, D. F., Telgt, D., Bousema, J. T., Hermsen, C. C., GEMERT, G. J. A. V., van der Meer, J. W. M., & Sauerwein, R. W. (2005) · PubMed · Cited by 88
Sant’Antonio, E., Guglielmelli, P., Pieri, L., Primignani, M., Randi, M. L., Santarossa, C., Rumi, E., Cervantes, F., Delaini, F., Carobbio, A., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25677 · Cited by 88
“0] per 100 patientyears).(34) Moreover, the ultimate impact of SVT on MPN patients' survival remains debated.”
BackgroundAntiphospholipid antibody syndrome
Lim, W. (2009) · Hematology · doi:10.1182/asheducation-2009.1.233 · Cited by 93
Uresandi, F., Monréal, M., García-Bragado, F., Domenech, P., Lecumberri, R., Escribano, P., Zamorano, J. L., Jiménez, S., Ruiz‐Artacho, P., Lozano, F., et al. (2013) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2013.07.008 · Cited by 94
Heit, J. A., Lahr, B. D., Petterson, T. M., Bailey, K. R., Ashrani, A. A., & Melton, L. J. (2011) · Blood · doi:10.1182/blood-2011-05-357343 · Cited by 81
Inherited Risk Factors for Venous Thrombosis
Cushman, M. (2005) · Hematology · doi:10.1182/asheducation-2005.1.452 · Cited by 85
Sex Differences in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism
Blanco-Molina, Á., Enea, I., Gadelha, T., Tufano, A., Bura-Rivière, A., Micco, P. D., Bounameaux, H., González, J., Villalta, J., & Monréal, M. (2014) · Medicine · doi:10.1097/md.0000000000000114 · Cited by 74
Isolated Gastrocnemius and Soleal Vein Thrombosis
Lautz, T. B., Abbas, F., Walsh, S. J. N., Chow, C., Amaranto, D. J., Wang, E., Blackburn, D. R., Pearce, W. H., & Kibbe, M. R. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181c1ae95 · Cited by 72
“7% to 4%.(22,23) A prospective randomized controlled trial is needed to definitively evaluate the risk-benefit ratio of therapeutic anticoagulation for IGSVT.”
BackgroundEffect of Low-Dose Aspirin on the Occurrence of Venous Thromboembolism: A Randomized Trial
Glynn, R. J., Ridker, P. M., Goldhaber, S. Z., & Buring, J. E. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00004 · Cited by 71
“Such patients have high recurrence rates, and extended low- or full-intensity warfarin therapy is effective in preventing recurrences (26, 27).”
BackgroundThe diagnosis and treatment of venous thromboembolism
Wells, P., & Anderson, D. (2013) · Hematology · doi:10.1182/asheducation-2013.1.457 · Cited by 70
Self-citationPulmonary Embolism and Atrial Fibrillation: Two Sides of the Same Coin? A Systematic Review
Ziki, M. D. A., Lip, G. Y. H., & Bikdeli, B. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0036-1598005 · Cited by 75
Performance of five different bleeding-prediction scores in patients with acute pulmonary embolism
Klok, F. A., Niemann, C., Dellas, C., Hasenfuss, G. P., Konstantinides, S., & Lankeit, M. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1239-x · Cited by 74
“With regard to VKA management, lower intensity treatment has been shown to be less effective in preventing recurrent VTE and not associated with a reduction in bleeding risks [23].”
BackgroundTreatment of DVT: how long is enough and how do you predict recurrence
Agnelli, G., & Becattini, C. (2007) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-007-0103-z · Cited by 70
“The first of these studies showed a superior efficacy of low-intensity anticoagulant regimen compared to placebo in the prevention of recurrent VTE [22].”
Do, E. J., Lenzini, P. A., Eby, C. S., Bass, A. R., McMillin, G. A., Stevens, S. M., Woller, S. C., Pendleton, R. C., Anderson, J. L., Proctor, P., et al. (2011) · The Pharmacogenomics Journal · doi:10.1038/tpj.2011.18 · Cited by 69
Stein, P. D., & Matta, F. (2010) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2010.03.002 · Cited by 69
Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension
Henkens, I. R., Hazenoot, T., Boonstra, A., Huisman, M. V., & Noordegraaf, A. V. (2012) · European Respiratory Journal · doi:10.1183/09031936.00039212 · Cited by 68
Periprocedural Anticoagulation Management of Patients With Venous Thromboembolism
McBane, R. D., Wysokiński, W. E., Daniels, P. R., Litin, S. C., Slusser, J. P., Hodge, D. O., Dowling, N. F., & Heit, J. A. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.199406 · Cited by 70
Determinants and measures of quality in oral anticoagulation therapy
Kaatz, S. (2007) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-007-0106-9 · Cited by 67
“Kearon and colleagues designed a trial to look at the optimal INR range for patients with venous thromboembolic disease [11].”
BackgroundDahri, K., & Loewen, P. (2007) · Thrombosis and Haemostasis · doi:10.1160/th07-04-0297 · Cited by 67
“Using a retrospective splitsample method (also known as “bootstrapping”) it was then compared to the mOBRI, Kuijer CPR, and a system evidently inferred from the ELATE trial (24) in a sample of Medicare recipients with atrial fibrillation.”
MethodSiragusa, S. M., Malato, A., Saccullo, G., Iorio, A., Ianni, M. D., Caracciolo, C., Coco, L. L., Raso, S., Santoro, M., Guarneri, F. P., et al. (2011) · American Journal of Hematology · doi:10.1002/ajh.22156 · Cited by 67
“Since the risk of recurrent VTE is believed to gradually diminish over time, many patients with idiopathic DVT may not require prolonged treatment with a vitamin K antagonist (VKA) [5,6].”
BackgroundCohen, A. T., Hamilton, M., Bird, A., Mitchell, S. A., Li, S., Horblyuk, R. V., & Batson, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160064 · Cited by 74
“Of the studies that reported the proportion of patients with unprovoked VTE, ASPIRE [34], ELATE [36] and AMPLIFY-EXT [17] reported>90% of patients with unprovoked VTE.”
BackgroundMethodInfluentialKhamashta, M. A., Taraborelli, M., Sciascia, S., & Tincani, A. (2016) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2016.04.002 · Cited by 81
Mfoumou, E., Tripette, J., Blostein, M. D., & Cloutier, G. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.11.001 · Cited by 74
“However, the advantage of OAT is counteracted by major bleeding, which is the main adverse event for this therapy [10,11, 37].”
New Anticoagulants for Treatment of Venous Thromboembolism
Weitz, J. I. (2004) · Circulation · doi:10.1161/01.cir.0000140901.04538.ae · Cited by 64
Self-citationSnow, V. T., Qaseem, A., Barry, P. P., Hornbake, E. R., Rodnick, J. E., Tobolic, T. J., Ireland, B. K., Segal, J. B., Bass, E. B., Weiss, K. B., et al. (2007) · The Annals of Family Medicine · doi:10.1370/afm.668 · Cited by 78
Franchini, M., Veneri, D., Salvagno, G. L., Manzato, F., & Lippi, G. (2006) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360600552678 · Cited by 74
Advances in Antithrombotic Therapy
Weitz, J. I., & Chan, N. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310960 · Cited by 62
Self-citationMuñoz-Torrero, J. F. S., Bounameaux, H., Pedrajas, J. M., Lorenzo, A., Rubio, S., Kearon, C., Hernández, L. M., & Monréal, M. (2011) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2011.05.114 · Cited by 61
Self-citationGuía para el diagnóstico, tratamiento y seguimiento de la tromboembolia pulmonar
Uresandi, F., Blanquer, J., Conget, F., de Gregorio, M. Á., Lobo, J. L., Otero, R., Rodríguez, E. P., Monréal, M., & Morales, P. (2004) · Archivos de Bronconeumología · doi:10.1016/s0300-2896(04)75596-9 · Cited by 80
Ageno, W., Rutjes, A. W., Pap, A. F., Buller, H. R., & Nisio, M. D. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-06-0474 · Cited by 62
Venous Thromboembolism in Children
Goldenberg, N. A., & Bernard, T. J. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.11.005 · Cited by 60
Venous thromboembolism in the elderly: A narrative review
Tritschler, T., & Aujesky, D. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.05.015 · Cited by 67
Thromboembolic Therapies in Dogs and Cats: An Evidence-Based Approach
Lunsford, K. V., & Mackin, A. J. (2007) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2007.01.010 · Cited by 59
Couturaud, F., Leroyer, C., Julian, J. A., Kahn, S. R., Ginsberg, J. S., Wells, P. S., Douketis, J. D., Mottier, D., & Kearon, C. (2009) · CHEST Journal · doi:10.1378/chest.09-0757 · Cited by 58
Self-citationGenetic Variations Associated With Recurrent Venous Thrombosis
Vlieg, A. V. H., Flinterman, L. E., Bare, L. A., Cannegieter, S. C., Reitsma, P. H., Arellano, A. R., Tong, C. H., Devlin, J. J., & Rosendaal, F. R. (2014) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.114.000682 · Cited by 58
Desch, K. C., Ozel, A. B., Halvorsen, M., Jacobi, P. M., Golden, K. L., Underwood, M. I., Germain, M., Trégouët, D., Reitsma, P. H., Kearon, C., et al. (2020) · Blood · doi:10.1182/blood.2019004161 · Cited by 58
Self-citationCosmi, B., Legnani, C., Iorio, A., Pengo, V., Ghirarduzzi, A., Testa, S., Poli, D., Tripodi, A., & Palareti, G. (2010) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2009.11.022 · Cited by 57
Genotype and Risk of Major Bleeding During Warfarin Treatment
Kawai, V. K., Cunningham, A., Colace, S. I., Driest, S. L. V., Oginni, A., Xu, H., Jiang, M., Li, C., Denny, J. C., Shaffer, C. M., et al. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.153 · Cited by 57
Khan, F. A., Tritschler, T., Kimpton, M., Wells, P. S., Kearon, C., Weitz, J. I., Buller, H. R., Raskob, G. E., Ageno, W., Couturaud, F., et al. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15491 · Cited by 58
Self-citationPiazza, G. (2013) · JAMA · doi:10.1001/jama.2012.164493 · Cited by 60
Mearns, E. S., Kohn, C. G., Song, J.-S., Hawthorne, J., Meng, J., White, C. M., Raut, M. K., Schein, J. R., & Coleman, C. I. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.05.035 · Cited by 61
“America Linear N 26 (800) W Kearon 2004 [36] RCT VTE 81 57 100% N.”
BackgroundWhole blood gene expression analyses in patients with single versus recurrent venous thromboembolism
LEWIS, D. A., Stashenko, G. J., Akay, O. M., Price, L. I., Owzar, K., Ginsburg, G. S., Chi, J., & Ortel, T. L. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.06.003 · Cited by 55
“Furthermore, recent studies in subjects with VTE have shown that an extended course of anticoagulation will decrease the risk of recurrence [7,8].”
BackgroundActivated Protein C Resistance and Factor V Leiden: A Review
Rosendorff, A., & Dorfman, D. M. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-866-apcraf · Cited by 59
Bauersachs, R. M., Beyer‐Westendorf, J., Bounameaux, H., Brighton, T., Cohen, A. T., Davidson, B. L., Holberg, G., Kakkar, A. K., Lensing, A. W. A., Prins, M. H., et al. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-02-0131 · Cited by 55
Self-citationRaskob, G. E., Buller, H. R., GROSSO, M. A., Zhang, G., Winters, S. M., Cohen, A. T., & Nisio, M. D. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-11-0830 · Cited by 56
“Edoxaban group Edoxaban score Outpatient Bleeding Risk Index (9, 13) Kuijer score (11) HAS-BLED score (14) Kearon score (12) ORBIT score (16) Rivaroxaban score (22) Warfarin group Edoxaban score Outpatient Bleeding Risk Index (9, 13) Kuijer score (11) HAS-BLED score (14) Kearon score (12) ORBIT score (16) Rivaroxaban…”
BackgroundInfluentialAcute Pulmonary Embolism: Don’t Ignore the Platelet
Sobieszczyk, P. S., Fishbein, M. C., & Goldhaber, S. Z. (2002) · Circulation · doi:10.1161/01.cir.0000035277.48823.01 · Cited by 59
Gal, G. L., Carrier, M., Kovacs, M. J., Betancourt, M. T., Kahn, S. R., Wells, P. S., Anderson, D. R., Chagnon, I., Solymoss, S., CROWTHER, M., et al. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04240.x · Cited by 54
Self-citationNieto, J. A., Solano, R., Iglesias, N. T., Ruiz‐Giménez, N., Fernández‐Capitán, C., Valero, B., Tiberio, G., Bura-Rivière, A., & Monréal, M. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.06.019 · Cited by 57
Woods, K., Douketis, J. D., Schnurr, T., Kinnon, K., Powers, P. J., & Crowther, M. A. (2004) · Thrombosis Research · doi:10.1016/j.thromres.2004.05.013 · Cited by 52
Self-citationVerhovsek, M. M., Motlagh, B., Crowther, M. A., Kennedy, C. C., Dolovich, L. R., Campbell, G., Wang, L., & Παπαϊωάννου, Α. (2008) · BMC Geriatrics · doi:10.1186/1471-2318-8-13 · Cited by 52
Self-citationSardar, P., Chatterjee, S., & Mukherjee, D. (2013) · Drugs · doi:10.1007/s40265-013-0082-7 · Cited by 50
Clark, N. P., Witt, D. M., Delate, T., Trapp, M., Garcia, D. A., Ageno, W., Hylek, E. M., & Crowther, M. A. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.8.960 · Cited by 49
Self-citationDeitelzweig, S. B., Lin, J., Kreilick, C., Hussein, M. A., & Battleman, D. S. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0056-z · Cited by 48
Long-term outcome of pulmonary embolism
Meyer, G., Planquette, B., & Sanchez, O. (2008) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3283063a51 · Cited by 52
Intracranial and fatal bleeding according to indication for long‐term oral anticoagulant therapy
Linkins, L., O'Donnell, M. J., Julian, J. A., & Kearon, C. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04016.x · Cited by 47
Self-citationSiddiq, F., Jalil, A., McDaniel, C. M., Brock, D. G., Pineda, C. C., BELL, R. D., & Lee, K. (2007) · Neurocritical Care · doi:10.1007/s12028-007-9011-5 · Cited by 47
Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice
Becquemont, L. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0542-2 · Cited by 50
“... of these trials will be available in the coming years and will hopefully definitively demonstrate the usefulness of a pharmacogenetically adapted dose of WA. The next explanation for so few randomised trials in the field is that the ultimate objective of such a study is to reduce the frequency of major bleeding ep…”
BackgroundDíaz, G., Marín, E., Vidal, R., Sueiro, A., Yusen, R. D., & Jiménez, D. (2006) · Thrombosis and Haemostasis · doi:10.1160/th05-10-0677 · Cited by 46
Recurrent Venous Thromboembolism: What Is the Risk and How to Prevent It
Palareti, G. (2012) · Scientifica · doi:10.6064/2012/391734 · Cited by 47
Diagnosis and management of pulmonary embolism in the elderly
Robert‐Ebadi, H., & Righini, M. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.03.009 · Cited by 43
“Several bleeding scores have been developed in the setting of VTE [80–83], but a recently published analysis on patients from the Swiss national VTE cohort showed poor performance of all these scores in patients N65 years (area under the ROC curves ranging from 0.”
MethodCouturaud, F., Pernod, G., Presles, É., Duhamel, E., Jégo, P., Provost, K., Pan‐Petesch, B., Sollier, C. B. D., Tromeur, C., Hoffmann, C., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.210971 · Cited by 47
Kovacs, M. J., Kahn, S. R., Wells, P. S., Anderson, D. R., Chagnon, I., Gal, G. L., Solymoss, S., Crowther, M. A., Perrier, A., Ramsay, T., et al. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03958.x · Cited by 49
Self-citationGuidelines on the Diagnosis and Management of Acute Pulmonary Embolism
Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F. M., Brady, A. J. B., Ferreira, D., Janssens, U., et al. (2008) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(09)60060-8 · Cited by 44
“Reduced VKA doses for extended treatment in patients with idiopathic VTE were shown to be effective and safe when compared with placebo,(320) but they were less effective and not safer when compared with conventional intensity anticoagulation.(321)”
BackgroundEndovascular treatment of peripheral vascular disease.
Allaqaband, S., Kirvaitis, R., Jan, F., & Bajwa, T. (2006) · Current problems in cardiology · doi:10.1016/j.cpcardiol.2009.05.001 · Cited by 25
Hypercoagulability in Athletes
Meyering, C. D., & Howard, T. (2004) · Current Sports Medicine Reports · doi:10.1249/00149619-200404000-00005 · Cited by 42
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease: Lessons From the COMPASS Trial
Coppens, M., Weitz, J. I., & Eikelboom, J. W. (2019) · Circulation Research · doi:10.1161/circresaha.118.313141 · Cited by 45
Self-citationLong-Term Anticoagulant Therapy of Patients with Venous Thromboembolism. What Are the Practices?
Mahé, I., Sterpu, R., Bertoletti, L., López‐Jiménez, L., Mellado, M., Trujillo‐Santos, J., Ballaz, A., Blasco, L., Marchena, P. J., Monréal, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128741 · Cited by 44
“(recent bleeding, anemia, renal insufficiency, chronic liver disease, inflammatory bowel disease, mental disturbances) that have been associated with an increased risk for bleeding [6,7].”
BackgroundKumano, O., Akatsuchi, K., & Amiral, J. (2021) · Biomedicines · doi:10.3390/biomedicines9030264 · Cited by 45
Rodger, M. A., Carrier, M., Gándara, E., & Gal, G. L. (2010) · Blood Reviews · doi:10.1016/j.blre.2010.06.001 · Cited by 44
Self-citationGore, J. M., Reed, G. W., Lessard, D., Pacifico, L., Emery, C., Crowther, M. A., Goldberg, R. J., & Spencer, F. A. (2009) · Thrombosis and Haemostasis · doi:10.1160/th08-06-0352 · Cited by 41
“The bleeding rates observed in the present study are significantly higher than those observed in acute and chronic clinical trials of VTE treatment conducted during periods similar to those of our study enrollment (1-3).”
BackgroundResultSelf-citationGaikwad, T., Ghosh, K., Kulkarni, B. P., Kulkarni, V. K., Ross, C. R., & Shetty, S. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.04.006 · Cited by 40
“A high INR predisposes to a high risk of bleeding, while an INR below the therapeutic target range indicates that the dose of warfarin is insufficient to protect against thromboembolic events (Hirsh et al., 2001; Kearon et al., 2003; Tapson et al., 2005; Wittkowsky, 2004).”
Background
Metadata
- Authors
- Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., Turpie, A. G., Geerts, W., Solymoss, S., van Nguyen, P., Demers, C., Kahn, S. R., Kassis, J., Rodger, M., Hambleton, J., & Gent, M.
- Affiliations
- McMaster University (CA)
- Western University (CA)
- Dalhousie University (CA)
- University of Ottawa (CA)
- University of New Brunswick (CA)
- University of Toronto (CA)
- McGill University (CA)
- Université Laval (CA)
- Université de Montréal (CA)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-08-14
- Volume
- 349
- Issue
- 7
- Pages
- 631-639
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2009013630
- Cited by
- 751
- References
- 12
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 3 · 2023: 12 · 2022: 8 · 2021: 12 · 2020: 17 · 2019: 25 · 2018: 38 · 2017: 26 · 2016: 29 · 2015: 27 · 2014: 31 · 2013: 58 · 2012: 45
- FWCI
- 34.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- warfarin, low-intensity anticoagulation, venous thromboembolism, recurrent venous thromboembolism, unprovoked venous thromboembolism, international normalized ratio, bleeding risk, anticoagulation intensity, long-term prophylaxis
- MeSH terms
- Age Factors, Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pulmonary Embolism, Risk Factors, Warfarin, Treatment Outcome, International Normalized Ratio, Venous Thrombosis, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.